Mind, Mood and Microbiota-Gut-Brain Axis in Psychiatric Disorders.

Journal: International journal of molecular sciences

Volume: 25

Issue: 6

Year of Publication: 2024

Affiliated Institutions:  Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. Neurosurgical Clinic, "Prof. Dr. N. Oblu" Emergency Clinical Hospital, Iași, Romania. Department of Neurosurgery, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.

Abstract summary 

Psychiatric disorders represent a primary source of disability worldwide, manifesting as disturbances in individuals' cognitive processes, emotional regulation, and behavioral patterns. In the quest to discover novel therapies and expand the boundaries of neuropharmacology, studies from the field have highlighted the gut microbiota's role in modulating these disorders. These alterations may influence the brain's processes through the brain-gut axis, a multifaceted bidirectional system that establishes a connection between the enteric and central nervous systems. Thus, probiotic and prebiotic supplements that are meant to influence overall gut health may play an insightful role in alleviating psychiatric symptoms, such as the cognitive templates of major depressive disorder, anxiety, or schizophrenia. Moreover, the administration of psychotropic drugs has been revealed to induce specific changes in a microbiome's diversity, suggesting their potential utility in combating bacterial infections. This review emphasizes the intricate correlations between psychiatric disorders and the gut microbiota, mentioning the promising approaches in regard to the modulation of probiotic and prebiotic treatments, as well as the antimicrobial effects of psychotropic medication.

Authors & Co-authors:  Toader Dobrin Costea Glavan Covache-Busuioc Dumitrascu Bratu Costin Ciurea

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Kumar K., Kumar A., Keegan R.M., Deshmukh R. Recent advances in the neurobiology and neuropharmacology of Alzheimer’s disease. Biomed. Pharmacother. 2018;98:297–307. doi: 10.1016/j.biopha.2017.12.053.
Authors :  9
Identifiers
Doi : 3340
SSN : 1422-0067
Study Population
Male,Female
Mesh Terms
Humans
Other Terms
MDD;antidepressants;antipsychotics;autism;brain–gut axis;gut microbiota;probiotics
Study Design
Study Approach
Country of Study
Publication Country
Switzerland